Sun, Jul 13, 2014, 6:15 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

craigsa620 6 posts  |  Last Activity: Jun 6, 2014 8:16 AM Member since: Oct 18, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Opko news on hGH-CTP

    by craigsa620 Jun 6, 2014 8:09 AM
    craigsa620 craigsa620 Jun 6, 2014 8:16 AM Flag

    I meant to write they are presenting results of Phase 2 trials not phase 1! Big difference and my mistake. Sorry!

  • Reply to

    Opko Homepage is down

    by firetire0705 Jun 2, 2014 4:13 PM
    craigsa620 craigsa620 Jun 6, 2014 8:13 AM Flag

    Works on my computer with no problem. Maybe they heard you were shorting and blocked you! :)

  • craigsa620 by craigsa620 Jun 6, 2014 8:09 AM Flag

    follow this link for some news on Opko that is just another step in developing their great pipeline.
    http://www.analystsreview.com/Jun-06-2014/OPK/report.pdf
    You may have to join to read, but its a free membership worth reading. Says they will be presenting results at a conference on phase 1 results of hGH-CTP trials on children which usually means positive results if they are presenting.

    Sentiment: Strong Buy

  • Reply to

    I'll go on record

    by miamianne67 Apr 9, 2014 4:23 PM
    craigsa620 craigsa620 Jun 6, 2014 7:57 AM Flag

    I agree completely Anne, and I would add that he wants to cement his legacy as one of the great biotech investors/builders ever, as I have been saying for years! He wants to go down in history and you don't get to do that (in a good way) by screwing over shareholders for self enrichment, which as you said is not a goal for someone at his age. I have believed from the start that Opko is all about legacy for Dr. Frost.

    Sentiment: Strong Buy

  • Reply to

    United Health Care Insurance Covers 4KScore

    by lottawatta2013 May 12, 2014 12:49 PM
    craigsa620 craigsa620 May 12, 2014 2:10 PM Flag

    Where has this been made public? Please provide a source, thank you. great if it can be verified.,

  • OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant

    Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy
    Achieved Key Secondary Endpoints of CR in the Acute and Overall Periods
    Achieved All Secondary Endpoints, Including No Significant Nausea
    Adverse Event Profile Consistent with Earlier Clinical Trials
    New Drug Application (NDA) Submission to U.S. FDA On Track for Mid-2014

    MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). The rolapitant arm in this trial, which enrolled patients receiving cisplatin-based, highly emetogenic chemotherapy (HEC), successfully achieved statistical significance over the standard therapy arm for the primary and all secondary endpoints. The adverse event profile for rolapitant remains consistent with that seen in previous clinical studies.

    The third Phase 3 study of rolapitant was an international, multicenter, randomized, double-blind, active-controlled study that enrolled 532 cancer patients receiving cisplatin-based chemotherapy regimens at a dose equal to or greater than 60 mg/m2. Patients were randomized to receive either control, which consisted of a 5-HT3 receptor antagonist plus dexamethasone, or 200 milligrams of oral rolapitant plus control. The rolapitant arm in this study successfully achieved statistical significance over the control arm for the primary endpoint of complete response (CR) in the delayed phase of CINV. In addition, the rolapitant arm also successfully achieved statistical significance over the control arm for the key secondary endpoints of CR in the acute (

    Sentiment: Strong Buy

OPK
8.99+0.22(+2.51%)Jul 11 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.